ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO589

Temporal Trends in Prevalence of Blood Pressure Screening and Hypertension After Introduction of Clinical Practice Guidelines on Hypertension in Canadian Children: A Time-Series Analysis

Session Information

Category: Hypertension and CVD

  • 1501 Hypertension and CVD: Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Wu, Michael, McMaster University, Hamilton, Ontario, Canada
  • Dart, Allison, University of Manitoba, Winnipeg, Manitoba, Canada
  • Kosowan, Leanne, University of Manitoba, Winnipeg, Manitoba, Canada
  • Roychoudhury, Smita, McMaster University, Hamilton, Ontario, Canada
  • Singer, Alexander, University of Manitoba, Winnipeg, Manitoba, Canada
  • Chanchlani, Rahul, McMaster University, Hamilton, Ontario, Canada
Background

In 2016 & 2017 respectively, new Canadian & American guidelines for assessing pediatric hypertension (HTN) were introduced. It is unknown whether these guidelines have impacted blood pressure (BP) screening & HTN prevalence in primary care settings.

Methods

The study included 438,297 children (3-18 years) from seven Canadian provinces with 1+ encounter in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) database between January 1, 2011 & December 31, 2019. The study cohort had 3 phases: Jan 1, 2011-Dec 31, 2015 (era 1), Jan 1, 2016 – Dec 31, 2017 (wash out) & Jan 1, 2018- Dec 31, 2019 (era 2). HTN was defined by NHLBI guideline up to December 31, 2017 & AAP 2017 guideline thereafter. We performed an interrupted time series analysis to assess impact of the guideline recommendations on BP screening and HTN prevalence.

Results

264,635 children in era 1 & 193,654 children in era 2 were evaluated. In era 1 and 2, there were 66,653 (25.2%) & 45,050 (23.3%) children, respectively with at least 1 BP measurement. Annual BP screening generally increased each year from 13.3% in 2011 to 20.2% in 2019. In Era 1, a total of 1.1% of children met HTN criteria with a mean onset age of 12.6 years (SD 4.1). In Era 2, a total of 2.0% of children met HTN criteria with a mean onset age of 14.1 years (SD 4.1). Time series analysis revealed a significant increase in BP screening and HTN after the guidelines’ introduction (p=0.04 and p=<0.0001 respectively).

Conclusion

BP screening and HTN prevalence generally increased between 2011 and 2019, with a significant increase in post-guideline BP documentation and children meeting HTN criteria following guideline implementation.

Proportion of children who received BP screening or who met HTN criteria from Jan 1, 2011 to Dec 31, 2019